Vascular Biogenics Ltd. (NASDAQ:VBLT) crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $2.18 and traded as low as $2.13. Vascular Biogenics shares last traded at $2.18, with a volume of 265,032 shares.
A number of equities research analysts have recently weighed in on the stock. Roth Capital raised their price target on shares of Vascular Biogenics from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Thursday, June 3rd. Zacks Investment Research downgraded shares of Vascular Biogenics from a “buy” rating to a “hold” rating in a report on Tuesday, July 13th. Finally, Chardan Capital reissued a “buy” rating and set a $5.00 price objective on shares of Vascular Biogenics in a report on Thursday, June 3rd. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $5.10.
The company has a market cap of $135.96 million, a price-to-earnings ratio of -4.27 and a beta of 1.00. The firm has a 50 day moving average price of $2.25 and a two-hundred day moving average price of $2.18.
Several hedge funds have recently added to or reduced their stakes in the company. HBK Sorce Advisory LLC acquired a new stake in shares of Vascular Biogenics in the 1st quarter valued at about $44,000. Vident Investment Advisory LLC grew its stake in Vascular Biogenics by 50.0% in the first quarter. Vident Investment Advisory LLC now owns 22,950 shares of the biopharmaceutical company’s stock valued at $46,000 after acquiring an additional 7,650 shares during the period. PVG Asset Management Corp bought a new stake in shares of Vascular Biogenics during the first quarter valued at approximately $53,000. Ikarian Capital LLC acquired a new position in shares of Vascular Biogenics during the first quarter worth approximately $1,601,000. Finally, Steel Peak Wealth Management LLC bought a new position in shares of Vascular Biogenics in the 1st quarter worth $48,000. 7.87% of the stock is currently owned by institutional investors.
Vascular Biogenics Company Profile (NASDAQ:VBLT)
Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of first-in-class treatments for cancer. Its programs include cancer, inflammation, and VB-600 which are focused on treating tumors, ovarian cancer, and chronic immune-related indications.
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.